Publication: Meme kanseri hastalarda gas6 ve reseptörlerine ait gen polimorfizmlerinin araştırılması
Abstract
Amaç: Meme kanseri, kansere bağlı ölümler içerisinde akciğer kanserinden sonra ikinci sırada yer almaktadır. Meme kanserinde genetik, epigenetik ve transkriptomik değişiklikler nedeniyle hücresel aktivitelerde yer alan proteinler ve yolaklar tedaviye yaklaşımda öncelikli tercih nedenlerindendir. Growth arrest specific-6(Gas6) K vitaminine bağımlı bir proteindir ve Tyro3, Axl ve Mer (TAM) olarak adlandırılan reseptörler ile etkileşime girerek biyolojik fonksiyonlarını yerine getirir. Son yapılan çalışmalar, Gas6/ TAM sinyalizasyonunun kanser patogenezinde rol oynayabileceğini göstermektedir. Bu çalışmada meme kanseri ve GAS6/ TAM reseptör polimorfizmleri arasındaki ilişkiyi araştırmayı amaçladık. Gereç ve Yöntem: Bu çalışmaya 32 meme kanserli hasta ile 29 sağlıklı gönüllü dahil edildi. Gas6 için rs8191974 ve rs1803628; Tyro-3 için rs2289743 ve rs2277537; Axl için rs2304232 ve rs2304234, Mer için rs869016 ve rs4374383 SNP ‘leri kullanıldı ve genotipleme Real-Time PZR ile gerçekleştirildi. Bulgular: Yapmış olduğumuz istatistiksel analizler sonucunda GAS6 ve TAM reseptörlerinin 8 SNP bakımından istatistiksel anlamlı bir fark göstermediklerini belirledik. Diğer taraftan, plazma GAS6 seviyelerinin meme kanseri hastalarında kontrole kıyasla oldukça yüksek olduğunu saptadık (p<0,001). Sonuçlar: Çalışmamız GAS6/ TAM polimorfizmin meme kanserindeki olası rolünün araştırıldığı ilk çalışmadır. Bu hipotezi doğrulamak ve hastalıkla en iyi şekilde ilişkilendirilecek olası genetik bileşenleri belirlemek için daha geniş popülasyonlara sahip başka çalışmalara ihtiyaç vardır.
Objective: Breast cancer is the second most common cancer-related death after lung cancer. Proteins and pathways involved in cellular activities due to genetic, epigenetic and transcriptomic changes in breast cancer are among the primary reasons for treatment approach. Growth arrest specific-6 (Gas6) is a vitamin K-dependent protein that interacts with receptors called Tyro3, Axl and Mer (TAM) to perform biological functions. Recent studies show that Gas6 / TAM signaling may play a role in cancer pathogenesis. In this study, we aimed to investigate the relationship between GAS6 / TAM receptor polymorphisms and breast cancer. Material and Methods: 32 patients with breast cancer and 29 healthy volunteers were included. rs8191974 and rs1803628 for the GAS6; rs2289743 and rs2277537 for the TYRO-3 gene; rs2304232 and rs2304234 for the AXL gene; rs869016 and rs4374383 for the MER were used and genotyping was performed by RT- PCR. Findings: As a result of our statistical analysis, we determined that GAS6 and TAM receptors showed no statistically significant difference in terms of 8 SNP. On the other hand, we found that plasma GAS6 levels were significantly higher in breast cancer patients compared to control (p<0.001). Discussion: Our study is the first to demonstrate the role of GAS6/ TAM polymorphism in breast cancer. Further studies with larger populations are needed in order to validate this hypothesis, as well as to determine the possible genetic components that could be best linked to the disease.
Objective: Breast cancer is the second most common cancer-related death after lung cancer. Proteins and pathways involved in cellular activities due to genetic, epigenetic and transcriptomic changes in breast cancer are among the primary reasons for treatment approach. Growth arrest specific-6 (Gas6) is a vitamin K-dependent protein that interacts with receptors called Tyro3, Axl and Mer (TAM) to perform biological functions. Recent studies show that Gas6 / TAM signaling may play a role in cancer pathogenesis. In this study, we aimed to investigate the relationship between GAS6 / TAM receptor polymorphisms and breast cancer. Material and Methods: 32 patients with breast cancer and 29 healthy volunteers were included. rs8191974 and rs1803628 for the GAS6; rs2289743 and rs2277537 for the TYRO-3 gene; rs2304232 and rs2304234 for the AXL gene; rs869016 and rs4374383 for the MER were used and genotyping was performed by RT- PCR. Findings: As a result of our statistical analysis, we determined that GAS6 and TAM receptors showed no statistically significant difference in terms of 8 SNP. On the other hand, we found that plasma GAS6 levels were significantly higher in breast cancer patients compared to control (p<0.001). Discussion: Our study is the first to demonstrate the role of GAS6/ TAM polymorphism in breast cancer. Further studies with larger populations are needed in order to validate this hypothesis, as well as to determine the possible genetic components that could be best linked to the disease.